Beta-2 microglobulin-deficient cells

a technology of microglobulin and cells, applied in the field of beta-2 microglobulindeficient cells, can solve the problems of reducing the clinical use of human pluripotent stem cells and their derivatives, requiring months of cell culture, and requiring significant costs, and achieving the effects of reducing the number of cells

Inactive Publication Date: 2014-05-15
UNIV OF WASHINGTON CENT FOR COMMERICIALIZATION
View PDF2 Cites 37 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the clinical use of human pluripotent stem cells and their derivatives has a major limitation—rejection of transplanted cells by the recipient due to differences in the major histocompatibility complex.
However, the development of individually matched cell line requires significant costs, months of cell culture, highly trained personnel, and extensive validation of the final product, all of which must be done with the approval of regulatory agencies.
This time-consuming, technically difficult, and expensive process is a major factor preventing stem cell-based therapies from entering clinical trials.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Beta-2 microglobulin-deficient cells
  • Beta-2 microglobulin-deficient cells
  • Beta-2 microglobulin-deficient cells

Examples

Experimental program
Comparison scheme
Effect test

example 1

Construction of Human Pluripotent Stem Cells with Knockout Mutations in B2M Genes

[0090]Human pluripotent stem cells were created with knockout mutations in both alleles of the beta-2 microglobulin (B2M) genes that encodes the common subunit required for surface expression of all HLA class I heterodimers (HLA-A, B, C, E, F and G). Adeno-associated virus (AAV) gene targeting vectors were used to construct B2M− / − (class I-negative) H1 human ESCs (University of Wisconsin). Human pluripotent stem cells were infected with AAV gene targeting vectors and the B2M gene was inactivated by homologous recombination. AAV mediated gene targeting methodology has been described previously in for example, Khan et al., 2011, Protocol, 482:482-501 and Khan et al., 1990, Science 248:1227-30. These references are hereby incorporated by reference in their entirety.

[0091]FIG. 1 describes the construction of HLA class I-negative human H1 ESCs cells using the adeno-associated virus (AAV) gene targeting vecto...

example 2

Expression of Single Chain Fusion HLA class I Proteins in B2M Knockout Cells

[0094]In mice, HLA class I-negative cells can be destructed by Natural Killer (NK) cells through the “missing self” mechanism. Bix et al., 1991, Nature 349, 329-331. Human NK cells have different receptors, but an analogous inhibition of NK cell killing is mediated through interactions of NK cell receptors with HLA-C, E and G. The “missing self” phenomenon has largely been described for class I-deficient hematopoietic cells, and the mouse transplantation data reported previously showing that many types of B2M− / − organs survived in B2M+ / + hosts suggests that it may be less important when transplanting cells form solid organs. However, given that it could significantly affect donor cell survival in some settings, specific HLA class I genes as single chain fusion proteins that suppress NK cell killing were introduced to the B2M− / − cells.

[0095]The strategy for expressing specific HLA class I genes in a B2M− / − ba...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
protein structureaaaaaaaaaa
cell massaaaaaaaaaa
secondary structureaaaaaaaaaa
Login to view more

Abstract

The invention provides isolated primate cells preferably human cells that comprise a genetically engineered disruption in a beta-2 microglobulin (B2M) gene, which results in deficiency in MHC class I expression and function. Also provided are the method of using the cells for transplantation and treating a disease condition.

Description

[0001]This application relates to and claims the benefit of priority to U.S. provisional application Ser. No. 61 / 477,474, filed Apr. 20, 2011, the disclosure of which is hereby incorporated by reference in its entirety.[0002]This invention was made with government support under grant numbers R01GM086497 and R01DK55759 awarded by the National Institutes of Health. The government has certain rights in the invention.BACKGROUND OF THE INVENTION[0003]Human pluripotent stem cells have the potential to treat diseases affecting almost every organ system. However, the clinical use of human pluripotent stem cells and their derivatives has a major limitation—rejection of transplanted cells by the recipient due to differences in the major histocompatibility complex.[0004]The major histocompatibility complex (MHC) is a cell surface multi-component molecule found in all vertebrates that mediates interactions of leukocytes with other leukocytes or other cells. The MHC gene family is divided into t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/00A61K35/28A61K35/12
CPCA61K35/28A61K39/0005C07K14/70539C07K2319/00C12N2740/17043C12N2750/14143C12N2800/30A61K2039/515A61K35/12A61P17/02A61P19/00A61P19/02A61P31/00A61P37/02A61P37/06A61P7/00A61P7/06A61P9/04A61P3/10
Inventor RUSSELL, DAVID W.
Owner UNIV OF WASHINGTON CENT FOR COMMERICIALIZATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap